Published in:
01-09-2010 | Correspondence
Cost Effectiveness of Venous Thromboembolism Pharmacological Prophylaxis in Total Hip and Knee Replacement: A Systematic Review
Authors:
Jonathan M. Plumb, Andreas Clemens, Brigitta U. Monz
Published in:
PharmacoEconomics
|
Issue 9/2010
Login to get access
Excerpt
The systematic review by Kapoor et al.[
1] published in issue 7 of
PharmacoEconomics concluded that there is insufficient evidence to determine the cost effectiveness of new oral anticoagulants for prophylaxis of venous thromboembolism (VTE) in total hip replacement (THR) and total knee replacement (TKR). This conclusion appears to be at odds with findings of respected health technology assessment (HTA) bodies such as the UK National Institute for Health and Clinical Excellence[
2,
3] and the Scottish Medicines Consortium[
4,
5] (both of which have conducted rigorous assessments of the evidence and concluded that use of either dabigatran etexilate or rivaroxaban is cost effective in this indication), as well as with the findings of two other peer-reviewed publications.[
6,
7] …
